Ryvu Therapeutics S.A.
RVU.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | PLN 624 | PLN 723 | PLN 647 | PLN 890 |
| - Cash | PLN 83 | PLN 103 | PLN 144 | PLN 160 |
| + Debt | PLN 71 | PLN 69 | PLN 74 | PLN 76 |
| Enterprise Value | PLN 612 | PLN 689 | PLN 577 | PLN 806 |
| Revenue | PLN 15 | PLN 12 | PLN 17 | PLN 26 |
| % Growth | 20.3% | -26.8% | -33.7% | – |
| Gross Profit | -PLN 29 | PLN 9 | PLN 13 | PLN 20 |
| % Margin | -191.4% | 72.8% | 78.1% | 77.1% |
| EBITDA | -PLN 20 | -PLN 28 | -PLN 21 | -PLN 31 |
| % Margin | -132.7% | -228.8% | -125.1% | -120.1% |
| Net Income | -PLN 25 | -PLN 34 | -PLN 25 | -PLN 35 |
| % Margin | -165.6% | -271.4% | -149.3% | -137.2% |
| EPS Diluted | -1.1 | -1.5 | -1.1 | -1.52 |
| % Growth | 26.7% | -36.4% | 27.6% | – |
| Operating Cash Flow | -PLN 17 | -PLN 24 | -PLN 44 | -PLN 28 |
| Capital Expenditures | -PLN 1 | -PLN 0 | -PLN 1 | PLN 0 |
| Free Cash Flow | -PLN 19 | -PLN 25 | -PLN 45 | -PLN 28 |